WO2008065529A2 - Appareil et méthodes d'évaluation de produits à base de cellules - Google Patents

Appareil et méthodes d'évaluation de produits à base de cellules Download PDF

Info

Publication number
WO2008065529A2
WO2008065529A2 PCT/IB2007/004215 IB2007004215W WO2008065529A2 WO 2008065529 A2 WO2008065529 A2 WO 2008065529A2 IB 2007004215 W IB2007004215 W IB 2007004215W WO 2008065529 A2 WO2008065529 A2 WO 2008065529A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
change
fluorescence
viability
Prior art date
Application number
PCT/IB2007/004215
Other languages
English (en)
Other versions
WO2008065529A3 (fr
Inventor
Moshe Flugelman
Original Assignee
Multigene Vascular Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multigene Vascular Systems, Inc. filed Critical Multigene Vascular Systems, Inc.
Publication of WO2008065529A2 publication Critical patent/WO2008065529A2/fr
Publication of WO2008065529A3 publication Critical patent/WO2008065529A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N3/00—Investigating strength properties of solid materials by application of mechanical stress
    • G01N3/24—Investigating strength properties of solid materials by application of mechanical stress by applying steady shearing forces

Definitions

  • the invention described herein pertains to an apparatus and methods for testing cell- based products, and more particularly to automated machinery that integrates various functions to determine cell viability at point of care locations.
  • Cell therapy is the most challenging and rapidly developing discipline of modern medicine.
  • the most pronounced use of cell therapy is bone marrow transplantation for hematological (blood) and cancer related syndromes.
  • the range of diseases that are addressed with cell therapy is rapidly expanding to include autoimmune diseases and cardiovascular diseases.
  • stem cells adult and embryonic
  • organ rejuvenation and cures for cancer are being tested with a variety of cells.
  • thousands of medical centers around the globe use cell therapy for multiple indications.
  • the handling of the cell-based products and the manipulation that the cells undergo prior to transfer to a patient are unregulated and are at the discretion of the researcher.
  • the major part of regulating cell-based products is quality control of the process and of the cell-based product. Since cells are dynamic and living entities, their condition can change rapidly. Biotech products in general, and cell-base products specifically, are highly sensitive to transfer and storage conditions.
  • Production of biotech products is usually done in a GMP facility under stringent conditions that include structured quality control and quality assurance processes.
  • the product is tested for several parameters such as sterility, or in the case of cell-based product, for cell viability. Once these tests are accomplished, the product is released for use. The final testing is referred to as "release testing.”
  • Biotech products are typically delivered to point of care facilities (e.g., hospitals or clinics), and may require special handling such as specific temperature and light conditions. These point of care facilities can be thousands of miles away from the manufacturing facility. Accordingly, even when the product is used immediately upon arrival (stem cell transplantation for example), or the facility and the patient are at the same hospital, unanticipated delays and/or exposure to extreme temperature can unknowingly damage or destroy the product.
  • point of care user e.g., physician, nurse, or technician
  • the patient have no convenient way of determining whether the quality and/or viability of the product has been compromised between the time the release testing was performed at the manufacturing facility and the time of use at the point of care. While several technologies exist that can test cell viability, none are equipped to do so simply, efficiently and with limited manipulation at the point of care.
  • the present invention provides an apparatus and methods for performing point of care release testing just prior to the use of a cell based product to provide the user information regarding the quality and/or viability of the product.
  • the invention also provides an algorithm specific to different cell types wherein the algorithm is used to determine, based on the percentage of non- viable cells, whether or not the cell-based product should be used.
  • the invention includes an apparatus for performing point of care release testing of cell-based products.
  • the apparatus can include means for thawing the cell based product, means for sampling the product, means for identifying viable or non-viable cells; and means for determining whether the product is useful for administering to a subject in need thereof.
  • the invention provides an apparatus for determining cell viability including at least one cell sampling chamber with a means for introducing one or more cells to the apparatus; at least one heating element disposed in operative proximity to the cell sampling system; at least one detection chamber in fluid communication with the cell sampling system; and an acquisition system for assessing the results obtained from the detection chamber, thereby determining the viability of the cells.
  • Suitable heating elements include a heat block, a hot plate, a water bath, a heating tank, and any combination thereof.
  • the heating element includes a means for agitating or mixing one or more cells contained within the cell sampling system.
  • the apparatus detection chamber includes a detection apparatus for evaluating the contents or characteristics of cells.
  • the detection apparatus comprises an optical or electrical detector. Suitable optical detectors include a spectrophotometer, a spectrometer, a spectrograph, a flow cytometer, and a fluorescence-activated cell sorter.
  • the apparatus can also include at least one labeling chamber with a means for labeling one or more cells.
  • the labeling chamber is in fluid communication with, and positioned between, the cell sampling system and the detection chamber.
  • the label is a protein, a DNA tag, a dye, an immuochemical agent, an antibody, an histochemical stain, a fluorescence probe, a quantum dot, radioactivity, a radio frequency identification tag, a change in viscosity, a change in opacity, a change in volume, a change in density, a change in pH, a change in temperature, a change in dielectric constant, a change in conductivity, or the change in the amount of any measurable entity within the one or more cells, or combinations thereof.
  • the label can be detected by fluorescence polarization, fluorescence intensity, fluorescence lifetime, fluorescence energy transfer, pH, ionic content, temperature, or combinations thereof.
  • the label identifies live cells, dead cells, or both.
  • the invention also provides for an apparatus that includes and acquisition system for assessing the results obtained from the detection chamber.
  • the acquisition system includes a microprocessor.
  • the apparatus can include an output device for displaying cell viability data wherein the device is in communication with the acquisition system.
  • the means for introducing one or more cells to the apparatus can be a vacuum system, an injection system or a sliding piston.
  • the apparatus is automated.
  • the invention also provides methods for determining cell viability including the steps of: introducing one or more cells into a cell sampling chamber; heating the cells or cell suspension with a heating element; detecting the cells in a detection chamber; and assessing the results obtained from the detection chamber, thereby determining the viability of the cells.
  • the multiple cells are introduced to the cell campling chamber. More preferably, the cells are introduced as a cell population suspension.
  • the cells can be detected with a spectrophotometer, a spectrometer, a spectrograph, a flow cytometer, or a fluorescence- activated cell sorter.
  • the cells are labeled with a protein, a DNA tag, a dye, an immuochemical agent, an antibody, an histochemical stain, a fluorescence probe, a quantum dot, radioactivity, a radio frequency identification tag, a change in viscosity, a change in opacity, a change in volume, a change in density, a change in pH, a change in temperature, a change in dielectric constant, a change in conductivity, or the change in the amount of any measurable entity within the cells, or combinations thereof.
  • the cells can be detected by fluorescence polarization, fluorescence intensity, fluorescence lifetime, fluorescence energy transfer, pH, ionic content, temperature, or combinations thereof.
  • the label identifies live cells, dead cells or both.
  • the results obtained from the detection system are assessed with a microprocessor.
  • the invention also includes a method for performing a point of care release test of a cell-based product by thawing the product, sampling the cell-based product in a sterile manner, determining viability of the cells, and determining if the cells are or are not suitable for use.
  • Figure 1 is a graphic representation showing cell staining with FACS.
  • Figure 2 is a flow chart schematic illustrating the apparatus operation.
  • Figure 3 is a flow chart schematic illustrating a preferred apparatus of the invention.
  • the invention includes an apparatus for performing point of care release testing of cell-based products.
  • the apparatus includes means for thawing the product, means for sampling the product, means for identifying viable or non-viable cells, and means for determining whether the product is useful for administering to a subject in need thereof.
  • a “viable” cell refers to cells that maintain homeostasis by the use of one or more energy consuming mechanisms.
  • a “viable” cell includes those in which productive oxidative metabolism occurs to produce the necessary energy; those in which only glycolysis is used to produce energy, as well as those which maintain cellular integrity, such as the ability to exclude, or actively remove, certain molecules from the interior of the cell, by energy consuming mechanisms.
  • a “viable” cell is capable of undergoing mitosis, cell growth, differentiation, and/or proliferation.
  • a “viable” cell is synonymous with a “living” cell, which includes cells that are quiescent (and thus not going through the cell cycle), but nonetheless alive because energy production and consumption occurs in such cells to maintain homeostasis.
  • cell membrane integrity is used as an indicator of cell viability, as damage to the protective cell membrane often results in loss of cell structure, leakage of critical intracellular contents, breakdown of essential ionic gradients and ultimately cell death.
  • Another indicator of cell viability is intracellular activity, the presence of which activity indicates that the cell is able to metabolize, grow, reproduce, maintain electrical membrane potential, or perform some other cell function critical for viability. Conversely, the lack of such activity is often used as an indicator of cell death.
  • the viability of a cell-based product in a test sample can be determined in order to assess the quality of the cell-based product.
  • Suitable instruments for determining cell viability include a fluorescence-activated cell sorter (FACS), a spectrophotometer, a spectrometer, a spectrograph, and a pH meter.
  • FACS fluorescence-activated cell sorter
  • spectrophotometer a spectrometer
  • a spectrograph a spectrograph
  • pH meter Alternatively, any standard method for determining cell viability can be utilized.
  • a biological sample means any substance isolated from or derived from any organism.
  • a biological sample can be tissue, blood, prokaryotic cells, eukaryotic cells, cell lines, cell organelles, antibodies, hybridomas, plasmids, viruses, plant tissue cells, bacteria, fungi including yeast, algae, protozoa, lichens, seeds, viruses or vectors.
  • the biological sample is a cell based product comprising one or more cells. Sterile samples of the cell-based product are collected to avoid contamination of the cells.
  • sample will be understood to encompass any fluid containing a particulate species of interest, wherein the particulate species is preferably a cell.
  • Suitable samples include cells such as blood cells, lymphocytes, and cells intended for use in cell therapy, which is the process of introducing new cells into a tissue in order to treat a disease.
  • Suitable samples can be isolated from any animal or mammalian source.
  • the samples are isolated from a human and preferably the samples are for human use (e.g., therapeutic or prophylactic treatment).
  • the following properties or applications of these methods will essentially be described for humans although they may also be applied to non- human mammals, e.g., apes, monkeys, dogs, mice, etc. The invention therefore can also be used in a plant or veterinarian context.
  • Cells useful in the invention include one or more of the following: hematopoietic stem cells, endothelial stem cells, hepatic stem cells, neuronal stem cells, muscle stem cells, cardiac stem cells, adult stem cells, embryonic stem cells, epidermal stem cells, adipose stem cells, mesenchymal stem cells, epithelial stem cells, stem cells obtained from a zygote, stem cells obtained from a blastocyst, stem cells from any organ, stem cells from any tissue, neurons, oligodendrocytes, astrocytes, smooth muscle cells, endothelial cells, cells from any organ (brain, pancreas, liver, kidney, heart, etc.), cells from any tissue (spinal cord, muscle, upper and lower gastrointestinal tracts, etc.) and combinations thereof.
  • Other suitable cells include both autologous (from the patient) and allogeneic (from another donor) stem cells, and cells that are genetically modified to express or over-express a gene or protein of interest.
  • the cells are optionally in suspension or are immobilized on a solid or semisolid support.
  • the cells can be in suspension on a microscope slide or in a specialized container needed for an instrumentation detection method such as in a cuvette or in a microtiter plate (e.g. 96 well titer plate).
  • the cells are adhered to a microscope slide using a cell adhesive solution such as poly-L-lysine, or are attached to a filter as a retained residue.
  • the apparatus of the invention further comprises a sample input means, preferably comprising metering elements to deliver a volumetric amount of sample fluid to the cell sampling chamber of the apparatus.
  • the means for introducing the cells to the apparatus is a vacuum system, an injection system, or a sliding piston.
  • the apparatus of the invention can also comprise an overflow reservoir for retaining excess fluid applied to the apparatus in excess of the amount metered into the cell sampling chamber, most preferably in fluid communication with the fluid sample input means wherein excess fluid is transferred to the overflow reservoir.
  • the overflow chamber is connected to the entry port to take off any excess fluid.
  • the term "in fluid communication" or "fluidly connected" is intended to define components that are operably interconnected to allow fluid flow between components.
  • Advantageous components of the apparatus of the invention include fluid sample input means, including volumetric metering means, channels for fluid flow between components, reagent reservoirs, mixing chambers, optical or electrical reading chambers, and filtering means that retain cells in the chamber.
  • the invention can also provide valves for controlling fluid flow between components, temperature control elements, separation channels, air outlet ports, sample outlet ports, mixing means including magnetic, acoustic and preferably mechanical mixers, liquid and dry reagents, and other components as described herein or known to the skilled artisan.
  • the fluid flow in the apparatus of the invention can be provided by mechanical means, including but not limited to using pumping means sufficient to achieve fluid movement. These means might include syringe pumps or HPLC pumps.
  • the fluid flow in the apparatus can also be provided by electrical, osmotic, electroosmotic means or any means know in the art for achieving fluid movement.
  • the sample is applied to the cell sampling chamber of the apparatus of the invention either directly or more preferably by transfer of a metered amount of a portion of the sample from a fluid sample input means to the chamber, for example, by the selective opening of valves controlling access to the chamber from the fluid sample input means.
  • the valves include, but are not limited to microvalves including mechanical, electrical and thermal valve mechanisms. Reagent reservoirs, wash buffer reservoirs, other fluidic components and the contents thereof are connected to one another and to the detection and cell accumulation chambers through channels, preferably microchannels as defined herein, controlled by such valves.
  • the invention also provides an apparatus that contains reservoirs and chambers for containing fluids, such as a wash buffer and staining solution.
  • the apparatus contains washing buffer used to detach nonspecifically bound particulates from the surface of the detection chamber, or a solution of a compound to which cells in the cell sampling chamber are going to be exposed.
  • the chambers may be pre-f ⁇ lled with liquid components and sealed using valving mechanisms, may be filled with dried reagents which are resolubilized by the addition of a fluid such as water, or may be filled at the time of use with prepared liquid reagents.
  • the cell based product can be delivered from the manufacturer at any temperature.
  • the cell based product is often delivered at less than about room temperature, at less about 4° C, at about 0 ° c or less than about -4 ° C.
  • the sample of the cell-based product is delivered from the manufacturer frozen on dry ice or frozen in liquid nitrogen.
  • the apparatus includes at least one cell thawing/heating element in operative proximity to the cell sampling system.
  • the means for heating or thawing cells includes a heat block, a hot plate, a water bath, a heating tank, or any combination thereof.
  • the heating element includes a means for agitating or mixing one or more cells contained within the cell sampling system.
  • the invention also provide at least one labeling chamber comprising a means for labeling the cells, wherein the labeling chamber is in fluid communication with, the cell sampling chamber and the detection chamber.
  • Stains and/or dyes are used to assess the viability of cells. Although a single stain/dye can be used to assess viability, the use of a combination of dyes has advantages. First, the use of a dye combination allows one skilled in the art to determine the ratio of the number of cells that show a response to the one dye versus the total number of cells or versus those cells that do not respond. Optionally, a second dye is used as a positive control to indicate that other cells are present that did not stain with the first dye.
  • the fluorescent dye passes through damaged cell membranes or the cell membrane of dead cells, but is unable to pass through undamaged cell membranes or the cell membrane of viable cells. Therefore, when the fluorescent probe is applied to a test sample in which both viable and dead cells are coexisting, the fluorescent probe selectively permeates into the dead cells and bonds with nucleic acids to emit a strong fluorescence.
  • the dead cell numbers are determined by measuring the fluorescence intensity with a fluorometer.
  • the fluorescent probe can include cationic fluorescent stains (dyes) for nucleic acids, such as ethidium homodimer and a cyanine fluorescent dye; ethidium halides such as ethidium bromide; propidium halides such as propidium iodide; and the like.
  • the dye solution or staining solution can be made by dissolving the dye directly in an aqueous solvent such as water, a buffer solution, such as phosphate buffered saline, or an organic water-miscible solvent such as dimethylsulfoxide (DMSO), dimethylformamide (DMF), or a lower alcohol such as methanol or ethanol, or acetonitrile.
  • aqueous solvent such as water, a buffer solution, such as phosphate buffered saline, or an organic water-miscible solvent such as dimethylsulfoxide (DMSO), dimethylformamide (DMF), or a lower alcohol such as methanol or ethanol, or acetonitrile.
  • DMSO dimethylsulfoxide
  • DMF dimethylformamide
  • a lower alcohol such as methanol or ethanol
  • acetonitrile acetonitrile
  • the dye is dissolved in about 100% DMSO and then diluted one or more times in water or buffer such that the dye is present in an effective amount.
  • An effective amount of dye is the amount sufficient to give a detectable fluorescent response in the cells being analyzed.
  • concentration of the dye is between about 0.01 ⁇ m and about 100 ⁇ M. It is generally understood in the art that the specific concentration of the staining solution is determined by the physical nature of the sample.
  • the optimal concentration of the dye is generally determined according to the cell density.
  • a range of dye concentrations are used to stain the sample or cell suspensions to determine the optimal dye concentration for the cell density of the sample.
  • dye concentrations from about 1 mM down are tested, preferably dye concentrations from about 30 ⁇ M down to about 1.1 ⁇ M.
  • the tested ranges of dye concentration represent the ranges used for the analysis.
  • the cells are illuminated at a suitable absorption wavelength.
  • a suitable wavelength is one that comes within the range of absorption wavelengths for each of the fluorescent dyes being used.
  • the mixture is illuminated by a light source capable of producing light at or near the wavelength of maximum absorption of the dye or dyes, such as by ultraviolet or visible lamp, an arc lamp, a laser, or even sunlight. Illumination of the dyed cells at a suitable wavelength results in one or more illuminated cells that are then analyzed according to their fluorescent response to the illumination.
  • the apparatus of the invention also provides a detection chamber for evaluating at least one content or characteristic of the cells comprised in the cell based product.
  • the invention includes detection systems for detecting, monitoring, quantifying or analyzing particulates, such as cells, in a detection chamber or in a cell accumulation chamber as described herein.
  • the illuminated cells are observed with any of a number of means for detecting a fluorescent response emitted from the illuminated cells, including but not limited to visible inspection, cameras and film or other imaging equipment, or use of instrumentation such as fluorometers, plate readers, laser scanners, microscopes, or flow cytometers, or by means for amplifying the signal such as a photomultiplier.
  • Detection systems useful in the manufacture and use of the apparatus of the invention include, but are not limited to, fluorescent, chemiluminescent, colorimetric, or scattering measurements.
  • the detection chamber or cell accumulation chamber can constitute a cuvette that is illuminated.
  • the detection apparatus can comprise an optical or electrical detector.
  • the detection apparatus comprises an optical detecting means.
  • the detection system comprises a simple visual detection means such as the development of a visible color.
  • non-optical detection systems such as electrochemical and radioactivity detecting are used.
  • Optical detecting means are provided as components of the apparatus of the invention.
  • the photodetectors of the invention are optimally provided to detect optical absorbance/transmittance, fluorescence, light-scattering or other optical signals, which are processed and translated into data on the position, number and viability of cells.
  • Absorbance measurements can be used to detect a dye or stain, such as a vital stain, or other analyte that changes the intensity of transmitted light by specifically absorbing energy (direct absorbance) or by changing the absorbance of another component in the system (indirect absorbance).
  • Absorbance measurements are preferably used in conjunction with enzyme-linked detection of the presence of a particulate within a detection chamber.
  • cellular particulates are detected by vital staining or other cell- specific staining (such as the use of dyes specific for certain cell types).
  • Optical path geometry is designed to ensure that the absorbance detector is focused on a light path receiving the maximum amount of transmitted light from the illuminated sample.
  • the invention provides an optical detector such as a spectrometer, a spectrograph, a flow cytometer, or a fluorescence-activated cell sorter (FACS).
  • Detection systems for use in the invention include spectroscopic, particularly monochromatic and stroboscopic, and electrochemical detectors (see, for example, Owicki et al., 1992, Biosensors & Biolelectronics 7: 255).
  • Spectroscopic methods using these detectors encompass spectroscopy, particularly ultraviolet and visible light absorbance, chemiluminescence, and fluorescence spectroscopy.
  • the detection systems of the invention comprise a light source and a photodetector; in certain embodiments (such as chemiluminescence), only the photodetector components are required.
  • Preferred spectroscopic methods include fluorescence.
  • an excitation source such as a laser is focused on an optically-transparent section of a disk.
  • Light from any analytically-useful portion of the electromagnetic spectrum is used to illuminate a particulate retained in an detection chamber or cell incubation chamber or surface.
  • the selection of light at a particular wavelength is paired with a material having geometries and refractive index properties resulting in total internal reflection of the illuminating light.
  • Fluorescence activated cell sorting is a powerful method that has been used to identify cells having a particular phenotype. See Touchberg et al. ⁇ Clincal Chem. 48(10):1819-1827 (2002)) for a review.
  • the FACS method has been used in combination with monoclonal antibodies as a reagent to detect cells as having a particular antigen, which is usually indicative of an expressed protein.
  • the method has been used extensively in relation to antigens expressed on the surface of cells, including cells that remain alive during, and after, FACS.
  • the method has been used with intracellular reporter gene systems based on the expression of a detectably labeled gene product by the cell.
  • the determination of viability can be used as a basis for sorting the cells for further experimentation. For example, all viable cells in a population are sorted, or all dead cells in a population are sorted. The cells are sorted manually or using an automated technique such as flow cytometry according to the procedures known in the art such as in U.S. Pat. No. 4,665,024
  • the cell viability can be calculated from the total cell number and viable cell number data obtained by the assay.
  • the invention includes a microprocessor.
  • the microprocessor of the invention is a programmable digital electronic component that incorporates the functions of a central processing unit (CPU) on a semiconducting integrated circuit (IC).
  • CPU central processing unit
  • IC semiconducting integrated circuit
  • the microprocessor receives input for the various steps of determining cell viability; controls the process of determining cell viability; runs the algorithm of quality determination; and displays the result to the user. Additionally, the microprocessor saves the history of the process for further statistical analysis.
  • a user interface e.g., computer
  • keypads e.g., keypads, light-pens, monitors, indicators, flat-panel displays, interface through communications options to host-devices or peripheral devices, and printers, plotters, and graphics devices are provided as devices of the invention.
  • Communication and telecommunications are provided through standard hard-wired interfaces (such as RS-232, IEEE-488M SCSI bus), infra-red and optical communications, short-or long-range telecommunications ("cellular" telecommunications radio-frequency), and internal or external modem for manual or automated telephone communications.
  • the apparatus of the invention determines the viability of the cells and if the cells are or are not suitable for use.
  • the microprocessor runs an algorithm designed to determine the product quality (cell viability).
  • the apparatus displays a GO or NO GO output to the user indicating if the product can or cannot be used.
  • a GO output is displayed when at least 50% of the cells sampled in the cell based product are viable.
  • the GO output is displayed when at least 60%, at least 70%, at least 80% or at least 90% of the cells sampled in the cell based product are viable.
  • the means for thawing can include a heating element integrated in the apparatus as part of a heat block or water bath.
  • the means for testing the product can include a FACS or spectrophotometer, pH meter, or other parameters important for determining the quality or viability of the product.
  • the means for identifying viable or non-viable cells can include cell staining methods known by those skilled in the art.
  • the means for determining whether or not to use the cell-based product can include an algorithm based on the number of viable or non-viable cells in the product, pH, or other relevant parameters.
  • the apparatus can also include means for displaying a message to the use indicating whether or not the product is suitable based on the outcome of the algorithm.
  • the invention can include a method for performing a point of care release test of a cell-based product by thawing the product, sampling it in a sterile manner, determining viability of the cells, and determining use or non-use of the cells.
  • the temperature of the cell-based can be manipulated to the appropriate utilization temperature prior to testing.
  • the cells are heated or thawed to room temperature or about 37° C.
  • Suitable thawing means include a controllable hot plate, a water bath and a tank containing an agitating frame.
  • the microprocessor determines the appropriate thawing protocol according to quantity and type of cells.
  • Samples of the cell-based product are examined to determine cell viability. Sterile samples are collected to avoid contamination of the cells.
  • the apparatus includes a vacuum system or a sliding piston to extract the solution from the container.
  • the apparatus uses any other standard method to extract the solution from the container.
  • the microprocessor controls each of the sampling phases and determines (accord to the respective input) the amount of material to be sampled.
  • a cell-based product can be transferred from the cell processing/manufacturing facility to the point of care facility in dry ice.
  • the cells can be thawed at a pace and time that were predetermined for the specific cell type by the manufacturer.
  • the apparatus can sample the product via a specific port in the product container and can stain the cell in the sample with a specific dye that is used to identify dead cells.
  • the stained sample can pass through the spectrophotometer which is part of the apparatus and based on the reading of the spectrophotometer, the percentage of cells that are dead can be determined.
  • the apparatus can use the percentage of dead cells in an algorithm and can display a message to the user whether the product is suitable or not for administration to a patient in need thereof.
  • Example 1 FACS Analysis Of CeIl Viability The viability of a test sample of cells was determined using a fluorescence-activated cell sorter (FACS). The red stain component of the LIVE/DEAD® Reduced Biohazard Viability/Cytotoxicity Kit #1 (Molecular Probes, cat# L-7013) was used for cell viability testing.
  • FACS fluorescence-activated cell sorter
  • the basis for this viability test was the differential permeability of live and dead cells to fluorescent stains.
  • the cell-impermeant, red fluorescent nucleic acid stain labels only cells with compromised membranes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Molecular Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur un appareil et des méthodes d'évaluation de produits à base de cellules et plus particulièrement sur des machines automatisées intégrant différentes fonctions diverses permettant de déterminer la viabilité de cellules ai niveau des points de soin.
PCT/IB2007/004215 2006-09-15 2007-09-17 Appareil et méthodes d'évaluation de produits à base de cellules WO2008065529A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88490806P 2006-09-15 2006-09-15
US60/884,908 2006-09-15

Publications (2)

Publication Number Publication Date
WO2008065529A2 true WO2008065529A2 (fr) 2008-06-05
WO2008065529A3 WO2008065529A3 (fr) 2008-09-04

Family

ID=39468322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004215 WO2008065529A2 (fr) 2006-09-15 2007-09-17 Appareil et méthodes d'évaluation de produits à base de cellules

Country Status (1)

Country Link
WO (1) WO2008065529A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093507A1 (fr) * 2011-12-21 2013-06-27 University Of Leeds Dosage de la viabilité cellulaire fonctionnelle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314805A (en) * 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
EP1688740A1 (fr) * 2003-11-05 2006-08-09 Universidad de Barcelona Procede et appareil de determination de la viabilite cellulaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314805A (en) * 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
EP1688740A1 (fr) * 2003-11-05 2006-08-09 Universidad de Barcelona Procede et appareil de determination de la viabilite cellulaire

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FUJIKAWA T ET AL: "Purification of Adult Hepatic Progenitor Cells Using Green Fluorescent Protein (GFP)-Transgenic Mice and Fluorescence-Activated Cell Sorting" JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 39, no. 2, 1 August 2003 (2003-08-01), pages 162-170, XP003009213 ISSN: 0168-8278 *
HERZENBERG LEONARD A ET AL: "The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford." CLINICAL CHEMISTRY OCT 2002, vol. 48, no. 10, October 2002 (2002-10), pages 1819-1827, XP002485814 ISSN: 0009-9147 *
LORINCZ M C ET AL: "Single cell analysis and selection of living retrovirus vector-corrected mucopolysaccharidosis VII cells using a fluorescence-activated cell sorting-based assay for mammalian beta-glucuronidase enzymatic activity." THE JOURNAL OF BIOLOGICAL CHEMISTRY 8 JAN 1999, vol. 274, no. 2, 8 January 1999 (1999-01-08), pages 657-665, XP002485815 ISSN: 0021-9258 *
MOLECULAR PROBES: "LIVE/DEAD Reduced biohazard viability/cytotoxicity Kit (L-7013)" 14 March 2001 (2001-03-14), MOLECULAR PROBES PRODUCT INFORMATION , XP002485816 page 2 - page 3 *
NOLAN G P ET AL: "Fluorescence-activated cell analysis and sorting of viable mammalian cells based on B-D-galactosidase activity after transduction of escherichia coli lacZ" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 85, 1 April 1988 (1988-04-01), pages 2603-2607, XP002969136 ISSN: 0027-8424 *
PARKS D R ET AL: "ANTIGEN-SPEFICI IDENTIFICATION AND CLONING OF HYBRIDOMAS WITH A FLUORESCENCE-ACTIVATED CELL SORTER" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 76, no. 4, 1 April 1979 (1979-04-01), pages 1962-1966, XP002951675 ISSN: 0027-8424 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093507A1 (fr) * 2011-12-21 2013-06-27 University Of Leeds Dosage de la viabilité cellulaire fonctionnelle

Also Published As

Publication number Publication date
WO2008065529A3 (fr) 2008-09-04

Similar Documents

Publication Publication Date Title
Manohar et al. Flow cytometry: principles, applications and recent advances
US20180100872A1 (en) Chip-based flow cytometer type systems for analyzing fluorescently tagged particles
Thomas et al. Cytokinesis-block micronucleus cytome assay in lymphocytes
JP4918281B2 (ja) 尿中有形成分分析装置
US9329130B2 (en) Systems and methods for counting cells and biomolecules
US8906697B2 (en) Method for the assessment of particles and a system and device for use in the method
US11911764B2 (en) System and method for cell imaging, analysis and measurement
US9933415B2 (en) Internal focus reference beads for imaging cytometry
US11364502B2 (en) Device and method for high-throughput multiparameter measurements in one or more live and fixed cells
CN105264374A (zh) 用于样品分析的方法、装置和系统
US20080182290A1 (en) Apparatus and methods for determining viability of cell-based products
WO2008065529A2 (fr) Appareil et méthodes d'évaluation de produits à base de cellules
Khan et al. Microfluidics add-on technologies for single-cell analysis
US20210252518A1 (en) Biological sample holder and handler
EP0817965A1 (fr) Procede d'identification de substances biologiquement actives de par leur effet sur des cellules vivantes
US5721135A (en) Apparatus for identifying biologically active substances by their effect on living cells
CN112782137B (zh) 10-50μm活体浮游生物活细胞流式细胞仪检测方法
CN113376079B (zh) 利用CountStar Rigel系统结合细胞染色来分析转染效率的方法
CN211741305U (zh) 一种悬浮式液态生物芯片检测系统
Rocha et al. Interaction Between Macrophages and Cryptococcus neoformans: Distinguishing Phagocytosed Versus External Fungi
CN118817684A (zh) 利用激光力细胞学的改进生物物理和生物化学细胞监测和定量
Sudirman et al. Single-fiber for minimally-invasive identification and collection of biological species
EP1181553A1 (fr) Procede et dispositif pour le comptage de cellules dans l'urine

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07870419

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07870419

Country of ref document: EP

Kind code of ref document: A2